CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer

Carotuximab effectively reduced the slow-cycling cell population and restored osimertinib sensitivity, offering a promising strategy for managing refractory NSCLC.